IS8529A - Rífamísínhliðstæður og notkun þeirra - Google Patents

Rífamísínhliðstæður og notkun þeirra

Info

Publication number
IS8529A
IS8529A IS8529A IS8529A IS8529A IS 8529 A IS8529 A IS 8529A IS 8529 A IS8529 A IS 8529A IS 8529 A IS8529 A IS 8529A IS 8529 A IS8529 A IS 8529A
Authority
IS
Iceland
Prior art keywords
rifamycin
analogues
rifamycin analogues
Prior art date
Application number
IS8529A
Other languages
English (en)
Inventor
Duzer John H Van
Arthur F Michaelis
William B Geiss
Douglas G Stafford
Raker Joseph
Xiang Y Yu
James M Siedlecki
Yang Yingfei
Original Assignee
Activbiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activbiotics Inc filed Critical Activbiotics Inc
Publication of IS8529A publication Critical patent/IS8529A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IS8529A 2003-12-23 2006-07-14 Rífamísínhliðstæður og notkun þeirra IS8529A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53223703P 2003-12-23 2003-12-23
PCT/US2004/043093 WO2005062882A2 (en) 2003-12-23 2004-12-21 Rifamycin analogs and uses thereof

Publications (1)

Publication Number Publication Date
IS8529A true IS8529A (is) 2006-07-14

Family

ID=34738771

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8529A IS8529A (is) 2003-12-23 2006-07-14 Rífamísínhliðstæður og notkun þeirra

Country Status (11)

Country Link
US (2) US7271165B2 (is)
EP (1) EP1701962A4 (is)
JP (1) JP2007516291A (is)
KR (1) KR20070006698A (is)
CN (1) CN1918172B (is)
AR (1) AR047352A1 (is)
AU (1) AU2004308399A1 (is)
CA (1) CA2550729A1 (is)
IS (1) IS8529A (is)
TW (1) TW200533340A (is)
WO (1) WO2005062882A2 (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004268531A1 (en) 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
JP2007513961A (ja) 2003-12-10 2007-05-31 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびその使用法
KR20070006698A (ko) * 2003-12-23 2007-01-11 액티브 바이오틱스 인코포레이티드 리파마이신 유사체 및 그의 용도
BRPI0614758A2 (pt) 2005-08-11 2011-04-12 Targanta Therapeutics Inc rifamicinas fosfonadas e usos destas para a prevenção e tratamento de infecções na articulação e osso
AU2006326456A1 (en) * 2005-12-14 2007-06-21 Activbiotics Pharma Llc Rifamycin analogs and uses thereof
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
JP5591112B2 (ja) * 2007-09-12 2014-09-17 ターガンタ セラピューティクス コーポレイション オリタバンシンの投与によってクロストリジウム・ディフィシレを抑制する方法
WO2010019511A2 (en) 2008-08-13 2010-02-18 Targanta Therapeutics Corp. Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
US8916193B2 (en) * 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
EP2675275B1 (en) 2011-02-14 2017-12-20 The Regents Of The University Of Michigan Compositions and methods for the treatment of obesity and related disorders
AU2012245079B2 (en) * 2011-04-18 2013-09-05 Commonwealth Scientific And Industrial Research Organisation Gas capture process
WO2013086415A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of Michigan Antimicrobial compounds
CN102846580A (zh) * 2012-10-17 2013-01-02 岳池县神龙科技研发有限公司 利福平胶囊在制备治疗痔疮药物中的用途
EP2991647B1 (en) 2013-05-02 2019-04-24 The Regents Of The University Of Michigan Deuterated amlexanox with improved metabolic stability
WO2014193722A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
ES2793174T3 (es) 2013-05-31 2020-11-13 Genentech Inc Anticuerpos antiteicoicos de pared y conjugados
RU2731055C2 (ru) 2014-12-03 2020-08-28 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
HK1244230A1 (zh) 2014-12-03 2018-08-03 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
PL236355B1 (pl) 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
WO2017132538A1 (en) 2016-01-29 2017-08-03 The Regents Of The University Of Michigan Amlexanox analogs
KR102204805B1 (ko) 2016-03-04 2021-01-20 제넨테크, 인크. 항체-리파마이신 접합체의 제조 방법
CN108794507B (zh) * 2017-04-26 2020-12-25 北京维德维康生物技术有限公司 一种利福昔明半抗原、人工抗原及其制备方法与应用
CN108047249A (zh) * 2017-12-21 2018-05-18 中国医药集团总公司四川抗菌素工业研究所 一种新型利福霉素衍生物及其制备方法和用途
CN108003177B (zh) * 2017-12-21 2020-04-14 中国医药集团总公司四川抗菌素工业研究所 一种苯并噁嗪利福霉素类衍生物及其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130099C (is) 1963-10-11
JPS58225093A (ja) 1982-06-25 1983-12-27 Kanegafuchi Chem Ind Co Ltd ベンゾチアジノリフアマイシン誘導体およびその製造法
JPS59231092A (ja) 1983-06-11 1984-12-25 Kanebo Ltd フエノチアジン型リフアマイシンおよびその医薬用途
US4690919A (en) 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS6122090A (ja) 1984-07-09 1986-01-30 Kanebo Ltd アミノ置換フエノチアジン型リフアマイシンおよびその医薬用途
JPS62240688A (ja) 1986-04-12 1987-10-21 Kanegafuchi Chem Ind Co Ltd ヒドロキシメチル基を有するアミノベンゾキサジノおよびアミノベンゾチアジノリフアマイシン誘導体
JPS62242687A (ja) 1986-04-15 1987-10-23 Kanegafuchi Chem Ind Co Ltd 置換ベンゾキサジノおよび置換ベンゾチアジノリフアマイシン誘導体
JP2544375B2 (ja) 1986-07-14 1996-10-16 鐘淵化学工業株式会社 アルキル置換ベンゾキサジノリフアマイシン誘導体
JPS6335578A (ja) 1986-07-31 1988-02-16 Kanegafuchi Chem Ind Co Ltd ベンゾキサジノまたはベンゾチアジノリフアマイシン誘導体
JPS6335579A (ja) 1986-07-31 1988-02-16 Kanegafuchi Chem Ind Co Ltd 含硫ベンゾキサジノリフアマイシン誘導体
JPS63233987A (ja) 1987-03-23 1988-09-29 Kanegafuchi Chem Ind Co Ltd ４′−ｔｅｒｔ−ブチルベンゾキサジノリフアマイシン誘導体
ES2088870T3 (es) 1988-03-18 1996-10-01 Kanegafuchi Chemical Ind Un derivado de benzoxazinorrifamicina sustituida, un procedimiento para preparar el mismo y un agente antibacteriano que contiene el mismo.
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
US5547683A (en) 1992-10-09 1996-08-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Method for producing microgranulated particle
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
CA2204007A1 (en) 1995-09-01 1997-03-13 Katsuji Yamashita Remedy for diseases caused by infection with helicobacter
US5981522A (en) 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
JP3963976B2 (ja) 1995-12-08 2007-08-22 株式会社カネカ クラミジア感染症治療剤
TW534813B (en) * 1997-02-28 2003-06-01 Kaneka Corp Treating agent for diseases due to infection with helicobacter
US6486161B1 (en) 1998-07-29 2002-11-26 Kaneka Corporation Use of rifamycin derivative for treating mastitis in a domestic animal
US6316433B1 (en) 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6900204B2 (en) 2001-09-06 2005-05-31 Activbiotics, Inc. Antimicrobial agents and uses thereof
WO2003045319A2 (en) 2001-11-21 2003-06-05 Activbiotics, Inc. Targeted therapeutics and uses thereof
AU2002364162A1 (en) 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
AU2002364562A1 (en) 2001-12-13 2003-06-30 Activbiotics, Inc. Metal complexes and formulations of rifamycin analogues and uses therof
US20040077533A1 (en) 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
US20030236265A1 (en) 2002-05-23 2003-12-25 Sayada Chalom B. Methods of treating bacterial infections and diseases associated therewith
WO2003101445A1 (en) 2002-06-03 2003-12-11 Activbiotics, Inc. Intravenous rifalazil formulation and methods of use thereof
WO2004019907A1 (en) 2002-08-29 2004-03-11 Activbiotics, Inc. Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
AU2004268531A1 (en) * 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
JP2007513961A (ja) 2003-12-10 2007-05-31 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびその使用法
KR20070006698A (ko) * 2003-12-23 2007-01-11 액티브 바이오틱스 인코포레이티드 리파마이신 유사체 및 그의 용도

Also Published As

Publication number Publication date
WO2005062882A2 (en) 2005-07-14
AR047352A1 (es) 2006-01-18
TW200533340A (en) 2005-10-16
US20050197333A1 (en) 2005-09-08
EP1701962A4 (en) 2008-03-05
US7271165B2 (en) 2007-09-18
AU2004308399A1 (en) 2005-07-14
US20100273765A1 (en) 2010-10-28
EP1701962A2 (en) 2006-09-20
CN1918172A (zh) 2007-02-21
WO2005062882A3 (en) 2005-12-29
CN1918172B (zh) 2011-09-14
CA2550729A1 (en) 2005-07-14
KR20070006698A (ko) 2007-01-11
JP2007516291A (ja) 2007-06-21

Similar Documents

Publication Publication Date Title
IS8529A (is) Rífamísínhliðstæður og notkun þeirra
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
IS3007B (is) Ónæmisbælandi efnasambönd og efnablöndur
DE502004009865D1 (de) Ür knochen
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
DE60326145D1 (de) Spielermittlungsverfahren
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
ATE379983T1 (de) Klettverschluss
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
IS8036A (is) Nýir sambræddir heteróhringir og notkun þeirra
DE602004003111D1 (de) Tiefen-basiertes Antialiasing
DE502004002225D1 (de) Selbstemulgierende Zubereitungen
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1562918T3 (da) Substituerede benzoxazinoner og anvendelser deraf
IS8489A (is) Umritunarstillar og aðferðir þeirra
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
DK1840121T3 (da) Glycinderivat og anvendelse heraf
IS7783A (is) Flóð og fjöru-ker
DK1662867T3 (da) Insekticid-forbindelser og fremgangsmåder til valg deraf
GB0318546D0 (en) Quinoxalinones and their use
NO20052356D0 (no) Redningsskoyte
NO20032673D0 (no) Ereksjonshjelpemiddel
NO20053898D0 (no) Use and proceeding at footballshoes